Compounds > ct-32228

Page last updated: 2024-11-11

ct-32228

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CT-32228: CT-32212 is the inactive isomer of CT-32228 used as a control; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	9886720
CHEMBL ID	36501
SCHEMBL ID	13622457
MeSH ID	M0492328

Synonyms (17)

Synonym
bdbm50141287
n-(4-bromo-phenyl)-6-(5-chloro-2-methyl-phenyl)-[1,3,5]triazine-2,4-diamine
ct-32228
CHEMBL36501 ,
5tt4a4mblr ,
521064-34-6
1,3,5-triazine-2,4-diamine, n-(4-bromophenyl)-6-(5-chloro-2-methylphenyl)-
ct 32228
unii-5tt4a4mblr
1,3,5-triazine-2,4-diamine, n2-(4-bromophenyl)-6-(5-chloro-2-methylphenyl)-
n-(4-bromophenyl)-6-(5-chloro-2-methylphenyl)-(1,3,5)triazine-2,4-diamine
SCHEMBL13622457
nsc-762419
nsc762419
Q27262860
EN300-1723029
2-n-(4-bromophenyl)-6-(5-chloro-2-methylphenyl)-1,3,5-triazine-2,4-diamine

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)	IC50 (µMol)	0.0600	0.0600	0.0600	0.0600	AID102975; AID1917048
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Process	via Protein(s)	Taxonomy
positive regulation of cytokine production	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
positive regulation of cytokine-mediated signaling pathway	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
phospholipid metabolic process	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
phosphatidic acid biosynthetic process	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
epidermis development	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
response to xenobiotic stimulus	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
CDP-diacylglycerol biosynthetic process	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
triglyceride biosynthetic process	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (1)

Process	via Protein(s)	Taxonomy
1-acylglycerol-3-phosphate O-acyltransferase activity	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Process	via Protein(s)	Taxonomy
endoplasmic reticulum	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
endoplasmic reticulum membrane	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
plasma membrane	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
specific granule membrane	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
endoplasmic reticulum	1-acyl-sn-glycerol-3-phosphate acyltransferase beta	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay ID	Title	Year	Journal	Article
AID1917054	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	A closer look at N
AID1917048	Inhibition of human LPAAT-beta by cell-free colorimetric assay	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	A closer look at N
AID102975	Inhibitory concentration against human lysophosphatidic acid acyltransferase-beta (LPAAT-beta) expressed in Sf9 insect cell membranes	2004	Bioorganic & medicinal chemistry letters, Mar-22, Volume: 14, Issue:6	Synthesis and SAR of 2-arylbenzoxazoles, benzothiazoles and benzimidazoles as inhibitors of lysophosphatidic acid acyltransferase-beta.
AID1917051	Cytotoxicity against human Jurkat cells assessed as cell growth inhibition	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	A closer look at N
AID1917060	Cytotoxicity against human HEC-1-A cells assessed as cell growth inhibition	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	A closer look at N
AID1917049	Cytotoxicity against human IM-9 cells assessed as cell growth inhibition	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	A closer look at N
AID1917059	Cytotoxicity against human AN3-CA cells assessed as cell growth inhibition	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	A closer look at N
AID1917058	Cytotoxicity against human MHOC-59 cell assessed as cell growth inhibition	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	A closer look at N
AID1917057	Cytotoxicity against human SK-OV-3 cells assessed as cell growth inhibition	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	A closer look at N
AID1917056	Cytotoxicity against mouse LL2 cells assessed as cell growth inhibition	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	A closer look at N
AID1917050	Cytotoxicity against human K562 cells assessed as cell growth inhibition	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	A closer look at N
AID1917053	Cytotoxicity against human HL-60 cells assessed as cell growth inhibition	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	A closer look at N
AID1917055	Cytotoxicity against human DU-145 cells assessed as cell growth inhibition	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	A closer look at N
AID1917052	Cytotoxicity against human Daudi cells assessed as cell growth inhibition	2022	European journal of medicinal chemistry, Nov-05, Volume: 241	A closer look at N
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (85.71)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (14.29)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.28 (24.57)
Research Supply Index	2.08 (2.92)
Research Growth Index	4.36 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.28)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (28.57%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (71.43%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
thymidine [no description available]	2.02	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	2.03	1	0	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
nsc 674495 NSC 674495: structure in first source	2.02	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Carcinoma, Lewis Lung A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.	0	2.93	1	0
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	0	2.93	1	0
Cancer of Lung [description not available]	0	2.93	1	0
Benign Neoplasms [description not available]	0	2.93	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	0	2.93	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	2.93	1	0
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	0	2.02	1	0
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	0	2.02	1	0
Female Genital Neoplasms [description not available]	0	2.02	1	0
Genital Neoplasms, Female Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE).	0	2.02	1	0
Leucocythaemia [description not available]	0	2.03	1	0
Acute Disease Disease having a short and relatively severe course.	0	2.03	1	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	0	2.03	1	0
Granulocytic Leukemia, Chronic [description not available]	0	2.03	1	0
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	0	2.03	1	0